Table 1 Characteristics of HCV treatment commenced patients in community settings
Variables | N (%) | |
|---|---|---|
Sex (n = 315) | Male | 212 (67.3) |
Female | 103 (32.7) | |
HCV genotype (n = 315) | 1 | 156 (49.7)a |
2 | 9 (2.9) | |
3 | 148 (47.1) | |
4 | 1 (0.3) | |
6 | 2 (0.6) | |
Age | ≤30 | 27 (8.6) |
31–40 | 87 (27.6) | |
41–50 | 112 (35.6) | |
51–60 | 70 (22.2) | |
> 60 | 19 (6.0) | |
Currently or recently drugs useb (n = 225) | Yes | 95 (44.2) |
No | 130 (57.8) | |
Receiving OST (n = 314) | Yes | 87 (27.7) |
No | 227 (72.3) | |
Antipsychotics use (n = 315) | Yes | 111 (35.2) |
No | 204 (64.8) | |
Prior HCV treatment | Peg-IFN or IFN plus Rib | 7 (2.2) |
DAA | 6 (1.9) | |
No | 302 (95.9) | |
Cirrhotic patients | Yes | 29 (9.2) |
No | 286 (90.8) | |
FibroScan ≥ 12.5 kPa (n = 112) | Yes | 4 (3.6) |
No | 108 (96.4) | |
APRI ≥ 1 (n = 308) | Yes | 46 (14.9) |
No | 262 (85.1) | |
Prescribed DAA (n = 314) | Sofosbuvir plus Daclatasvir | 112 (35.7) |
Sofosbuvir plus Ledipasvir | 95 (30.2) | |
Epclusa | 62 (19.7) | |
Zepatier | 31 (9.9) | |
Sofosbuvir plus Velpatasvir | 10 (3.2) | |
Paritaprevir/ritonavir plus Ombitasvir plus Dasabuvir | 3 (1) | |
Elbasvir/Grazoprevir | 1 (0.3) | |
Treatment duration (n = 315) | 8 weeks | 3 (1) |
12 weeks | 300 (95.2) | |
24 weeks | 12 (3.8) | |